Brief: Biostage regenerates esophagus in pre-clinical work with Mayo Clinic
12/05/2016 12:31
May 12 (Reuters) - Biostage Inc BSTG.O :
* Successfully regenerates esophagus in groundbreaking
pre-clinical work with Mayo Clinic; data provides 'proof of
concept' to seek FDA approval for clinical trials
* Says Biostage currently expects to complete its IND filing
by year-end 2016
Source text for Eikon: urn:newsml:reuters.com:*:nPnb8k7Sfa
Further company coverage: BSTG.O
(Bengaluru Newsroom: +1-646-223-8780)
Recent news on Harvard Apparatus Regenerative Technology
See all newsBrief: Harvard Apparatus Regenerative Technology Announces Strategic Collaboration With Children’S Hospital Capital Institute Of Pediatrics In Beijing, China To Advance Treatment For Esophageal Atresia
Brief: Biostage Activated Mayo Clinic As The First Site For Clinical Trial In Severe Esophageal Disease
Brief: Biostage Amends CEO Employment Agreement
Brief: Biostage Inc Files For Firm Commitment Public Offering Of 1.03 Million Units - SEC Filing
Brief: Biostage Announces Appointment Of New Chief Financial Officer